Patheon

Last updated
Patheon N.V.
Company typeSubsidiary
IndustryContract Development Manufacturing Organization
Headquarters
Key people
Marc N. Casper (President & CEO)
Parent Thermo Fisher Scientific
Website www.patheon.com

Patheon is a service brand within Thermo Fisher Scientific's brand portfolio. Contract development and manufacturing organization (CDMO) services offered under the Patheon brand include small molecule API, biologics, viral vectors, cGMP plasmids, formulation, clinical trials solutions, logistics and commercial manufacturing and packaging. In 2017, Patheon was acquired by Thermo Fisher Scientific to form its Pharma Services business.

Contents

History

Patheon was founded in Fort Erie, Ontario in 1974 as Custom Pharmaceuticals Ltd. In 1990, it began to expand to US markets. Custom Pharmaceuticals changed its name to Patheon in 1993 and was first publicly traded that year on the Toronto Stock Exchange. [1]

In 2004, Patheon acquired MOVA, a drug manufacturer based in Puerto Rico, US. The deal proved unprofitable, and in 2007, the New York equity firm JLL Partners provided Patheon $150 million to restructure. Two years later, after a failed takeover bid by Lonza Group, JLL Partners bought a controlling interest in the company. [2]

In December 2012, Patheon acquired Banner Pharmacaps, a drug manufacturer specializing in softgels, for $255 million. (Patheon changed the company's name the following year to "Banner Life Sciences"). [3] In a $2.6 billion deal, Patheon merged with the pharmaceutical division of Royal DSM NV in 2014 to become a joint venture after JLL Partners bought a controlling stake in the latter as well, adding significantly to Patheon's European production capacity. [4] [5]

In 2015, Patheon acquired Agere Pharmaceuticals, an Oregon company specializing in drug solubility, and IRIX, a maker of specialist Active Pharmaceutical Ingredients in South Carolina, the latter for $162.78 million. [6] [7]

On August 29, 2017, Thermo Fisher Scientific completed its acquisition of Patheon for $7.2 billion. [8]

Dosage Forms, Products

Patheon does not own any of the licenses of the products it manufactures and is often listed as the manufacturer on packaging, with the product license holder's brand name, product name and corporate identity being used. Clients include such pharmaceutical brands as Merck & Co, Novartis, Takeda and Sanofi Aventis, with biotechnology customers including Amgen and Avanir Pharmaceuticals. As of 2016, Patheon had manufactured or developed more than 800 products. [9]

In 2016, Patheon's manufacturing sites included sites in Canada, the continental US, Puerto Rico, France, the United Kingdom, Italy, Austria, Germany, the Netherlands, Japan, and Australia. [10]

Patheon manufactures products in various dosage forms including oral solids (tablets, capsules) and injectable sterile products (vials, ampoules, pre-filled syringes containing liquids, powders and lyophilisates).

Related Research Articles

Affymetrix is now Applied Biosystems, a brand of DNA microarray products sold by Thermo Fisher Scientific that originated with an American biotechnology research and development and manufacturing company of the same name. The Santa Clara, California-based Affymetrix, Inc. now a part of Thermo Fisher Scientific was co-founded by Alex Zaffaroni and Stephen Fodor. Stephen Fodor and his group, based on their earlier development of methods to fabricate DNA microarrays using semiconductor manufacturing techniques.

Shire plc was a UK-founded Jersey-registered specialty biopharmaceutical company. Originating in the United Kingdom with an operational base in the United States, its brands and products included Vyvanse, Lialda, and Adderall XR. Shire was acquired by Takeda Pharmaceutical Company on 8 January 2019.

<span class="mw-page-title-main">DSM (company)</span> Dutch multinational corporation

Koninklijke DSM N.V., was a Dutch multinational corporation active in the fields of health, nutrition and materials. Headquartered in Heerlen, at the end of 2017 DSM employed 21,054 people in approximately 50 countries and posted net sales of €8.632 billion in 2018 and €9.204 billion in 2021. In May 2023 it merged with the Swiss company Firmenich to form a new entity named dsm-firmenich.

Fisher Scientific International, Inc. was a laboratory supply and biotechnology company that provided products and services to the global scientific research and clinical laboratory markets until its merger with Thermo Electron in 2006, after which it became Thermo Fisher Scientific. The company offered products and services to over 350,000 customers located in approximately 150 countries including pharmaceutical and biotechnology companies, secondary and higher education institutions, hospitals and medical research institutions, and quality control, process control and research and development laboratories.

<span class="mw-page-title-main">Perrigo</span> Irish tax-registered pharmaceutical

Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.

<span class="mw-page-title-main">Astellas Pharma</span> Japanese pharmaceutical company

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd..

<span class="mw-page-title-main">Teva Pharmaceuticals</span> Israeli pharmaceutical company

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (API's) and, to a lesser extent, contract manufacturing services and an out-licensing platform.

<span class="mw-page-title-main">Daiichi Sankyo</span> Japanese pharmaceutical company

Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent.

<span class="mw-page-title-main">Actavis</span> Global pharmaceutical company

Actavis Generics is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial presence across approximately 100 countries. The company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, United States.

Endo International plc is an American Irish-domiciled generics and specialty branded pharmaceutical company that generated over 93% of its 2017 sales from the U.S. healthcare system. While Endo's management, operations, and customers are almost exclusively U.S.–based, in 2013 Endo executed a corporate tax inversion to Ireland to avoid U.S. corporate taxes on their U.S. drug sales, and to avail of Ireland's corporate tax system.

<span class="mw-page-title-main">Thermo Fisher Scientific</span> Provisioner of scientific consumables, equipment, and services

Thermo Fisher Scientific Inc. is an American-headquartered life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021).

<span class="mw-page-title-main">Sun Pharma</span> Indian multinational pharmaceutical company

Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries across the globe. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world. The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynecology, respiratory, oncology, dental and nutritionals. 

Alfa Aesar was a supplier of reagents and materials for use in research and development, and analysis. The company had facilities in a variety of countries and manufactured many of the chemicals they sold. The company was bought by Thermo Fisher Scientific in 2015, having previously existed as part of the Johnson Matthey Fine Chemicals & Catalysts Division. In 2021, Alfa Aesar products were rebranded under the Thermo Scientific brand name.

Curia is a contract research and manufacturing organization that provides drug discovery, development, cGMP manufacturing and aseptic fill and finish to the pharmaceutical and biotechnology industries. Founded in 1991, Curia operates in the United States, Europe and Asia, with its headquarters located in Albany, New York. Curia has announced deals and collaborations with such companies as Pfizer Inc., Merck & Co., Eli Lilly and Company, Takeda, Genentech, Bristol-Myers Squibb Co. and GE.

<span class="mw-page-title-main">Piramal Group</span> Indian conglomerate

The Piramal Group is an Indian multinational conglomerate that has presence across various sectors such as healthcare, life sciences, drug discovery, financial services, alternative investment and real estate.

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States. One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.

Horizon Therapeutics was a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. Amgen acquired the company in October 2023.

Catalent, Inc. is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 14,000 people, including approximately 2,400 scientists and technicians. In fiscal year 2020, it generated over $3 billion in annual revenue.

Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox.

Alvogen is an Icelandic pharmaceutical company founded in 2009. In 2014, a controlling stake in the company was acquired by CVC Capital Partners and Temasek Holdings. Alvogen has about 350 different medical and non-medical products, and both produces its own products and markets the products of brand name pharmaceutical companies.

References

  1. "History and Milestones". Patheon. Archived from the original on 2016-05-27. Retrieved May 18, 2016.
  2. Hodson, Peter (2013-12-13). "5 takeover failures revisited". Financial Post. Archived from the original on 2022-01-06. Retrieved 2022-01-06.
  3. Evans, Matt (Jul 1, 2013). "Patheon changing Banner Pharmacaps' name" . Triad Business Journal. Archived from the original on 2016-06-04. Retrieved 2022-01-06.
  4. Xu, Jodi; Carey, David; Noel, Andrew (19 November 2013). "JLL Forms New Pharma Firm With DSM in $2.6 Billion Deal" . Bloomberg. Archived from the original on 2022-07-06.
  5. Stanton, Dan (26 Aug 2014). "Patheon propels itself into US biologics market in Gallus acquisition". BioPharma-Reporter.com.
  6. Ruckin, Claire (9 March 2017). "TRLPC-Patheon to raise 150 mln euro loan for IRIX acquisition". Reuters.
  7. "Oregon pharma company sold to North Carolina manufacturer". www.bizjournals.com. Retrieved 2022-01-06.
  8. "Thermo Fisher Scientific to Acquire Patheon for $7.2B - GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business - GEN". GEN. 15 May 2017.
  9. "Patheon by the Numbers" (PDF). patheon.com. Patheon. Retrieved May 18, 2016.
  10. "Sites". Patheon.